JP7808039B2 - 部位特異的Ｎｏｔｃｈ活性化分子およびその使用 - Google Patents

部位特異的Ｎｏｔｃｈ活性化分子およびその使用

Info

Publication number
JP7808039B2
JP7808039B2 JP2022544653A JP2022544653A JP7808039B2 JP 7808039 B2 JP7808039 B2 JP 7808039B2 JP 2022544653 A JP2022544653 A JP 2022544653A JP 2022544653 A JP2022544653 A JP 2022544653A JP 7808039 B2 JP7808039 B2 JP 7808039B2
Authority
JP
Japan
Prior art keywords
antigen
binding
antibody
cells
notch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022544653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530797A (ja
Inventor
ジェン ニン エイドリアン ウィー
慶直 類家
弘康 村松
智之 井川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of JP2023530797A publication Critical patent/JP2023530797A/ja
Priority to JP2025171548A priority Critical patent/JP2026010057A/ja
Application granted granted Critical
Publication of JP7808039B2 publication Critical patent/JP7808039B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2022544653A 2020-06-30 2021-06-30 部位特異的Ｎｏｔｃｈ活性化分子およびその使用 Active JP7808039B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025171548A JP2026010057A (ja) 2020-06-30 2025-10-10 部位特異的Ｎｏｔｃｈ活性化分子およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020112553 2020-06-30
JP2020112553 2020-06-30
PCT/JP2021/024655 WO2022004761A1 (en) 2020-06-30 2021-06-30 Site specific notch-activating molecule and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025171548A Division JP2026010057A (ja) 2020-06-30 2025-10-10 部位特異的Ｎｏｔｃｈ活性化分子およびその使用

Publications (2)

Publication Number Publication Date
JP2023530797A JP2023530797A (ja) 2023-07-20
JP7808039B2 true JP7808039B2 (ja) 2026-01-28

Family

ID=79316658

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022544653A Active JP7808039B2 (ja) 2020-06-30 2021-06-30 部位特異的Ｎｏｔｃｈ活性化分子およびその使用
JP2025171548A Pending JP2026010057A (ja) 2020-06-30 2025-10-10 部位特異的Ｎｏｔｃｈ活性化分子およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025171548A Pending JP2026010057A (ja) 2020-06-30 2025-10-10 部位特異的Ｎｏｔｃｈ活性化分子およびその使用

Country Status (6)

Country Link
US (1) US20230383011A1 (https=)
EP (1) EP4172210A4 (https=)
JP (2) JP7808039B2 (https=)
CN (1) CN115943163A (https=)
TW (2) TW202547877A (https=)
WO (1) WO2022004761A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024336361A1 (en) * 2023-09-08 2026-04-23 Mlab Biosciences, Inc. Bifunctional proteins and uses thereof
CN121490066A (zh) * 2025-12-31 2026-02-10 北京大学第一医院(北京大学第一临床医学院) 重组蛋白制剂anxa2作为notch激动剂的新应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004524269A (ja) 2000-09-22 2004-08-12 ジェネンテック・インコーポレーテッド ノッチレセプターアゴニスト及び用途
JP2010506596A (ja) 2006-10-19 2010-03-04 ジェネンテック インコーポレイテッド 抗ノッチ３アゴニスト抗体とノッチ３関連疾患の治療におけるその使用
JP2012056934A (ja) 2010-09-13 2012-03-22 Chiba Univ 抗ノッチ１アゴニスト抗体を含む組織再生治療剤及び該抗体を使用する組織再生治療方法
JP2013231018A (ja) 2012-05-02 2013-11-14 Juntendo 腎疾患治療薬
US20140093496A1 (en) 2011-02-25 2014-04-03 Chugai Seiyaku Kabushiki Kaisha Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
WO2017079448A1 (en) 2015-11-06 2017-05-11 The Board Of Trustees Of The University Of Illinois Ox40l-jagged-1 chimeric polypeptides and uses thereof
WO2018017827A1 (en) 2016-07-22 2018-01-25 Fred Hutchinson Cancer Research Center Bi-specific molecule for cell-specific notch inhibition and related methods and compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11613567B2 (en) * 2017-03-24 2023-03-28 Ohio State Innovation Foundation Modulators of notch signaling and methods of use thereof
EP4004040A4 (en) * 2019-07-29 2023-08-16 Fred Hutchinson Cancer Center METHODS AND COMPOSITIONS FOR INDUCING NOTCH SIGNALING IN TUMOR MICROOM ENVIRONMENTS

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004524269A (ja) 2000-09-22 2004-08-12 ジェネンテック・インコーポレーテッド ノッチレセプターアゴニスト及び用途
JP2010506596A (ja) 2006-10-19 2010-03-04 ジェネンテック インコーポレイテッド 抗ノッチ３アゴニスト抗体とノッチ３関連疾患の治療におけるその使用
JP2012056934A (ja) 2010-09-13 2012-03-22 Chiba Univ 抗ノッチ１アゴニスト抗体を含む組織再生治療剤及び該抗体を使用する組織再生治療方法
US20140093496A1 (en) 2011-02-25 2014-04-03 Chugai Seiyaku Kabushiki Kaisha Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
JP2013231018A (ja) 2012-05-02 2013-11-14 Juntendo 腎疾患治療薬
WO2017079448A1 (en) 2015-11-06 2017-05-11 The Board Of Trustees Of The University Of Illinois Ox40l-jagged-1 chimeric polypeptides and uses thereof
WO2018017827A1 (en) 2016-07-22 2018-01-25 Fred Hutchinson Cancer Research Center Bi-specific molecule for cell-specific notch inhibition and related methods and compositions

Also Published As

Publication number Publication date
EP4172210A4 (en) 2024-10-16
WO2022004761A1 (en) 2022-01-06
EP4172210A1 (en) 2023-05-03
TW202216775A (zh) 2022-05-01
TW202547877A (zh) 2025-12-16
US20230383011A1 (en) 2023-11-30
JP2026010057A (ja) 2026-01-21
CN115943163A (zh) 2023-04-07
JP2023530797A (ja) 2023-07-20

Similar Documents

Publication Publication Date Title
TWI799824B (zh) Ｄｌｌ３靶向之多特異性抗原結合分子及其用途
TWI900776B (zh) 密連蛋白6靶向多特異性抗原結合分子及其用途
WO2021200896A1 (en) Immune activating multispecific antigen-binding molecules and uses thereof
JP2026010057A (ja) 部位特異的Ｎｏｔｃｈ活性化分子およびその使用
WO2022034920A1 (en) One-armed antigen-binding molecules and uses thereof
JP7603785B2 (ja) がんの治療に用いるための細胞傷害誘導治療剤
HK40082572A (en) Site specific notch-activating molecule and uses thereof
HK40085740A (en) One-armed antigen-binding molecules and uses thereof
HK40076462B (zh) 靶向 dll3 的多特异性抗原结合分子及其用途
EA049685B1 (ru) Таргетирующие dll3 мультиспецифические антигенсвязывающие молекулы и их применения
HK40076462A (en) Dll3-targeting multispecific antigen-binding molecules and uses thereof
HK40074344A (en) Immune activating multispecific antigen binding molecules and uses thereof
EA047044B1 (ru) Таргетирующие клаудин-6 мультиспецифические антигенсвязывающие молекулы и их применения

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240216

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250523

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260116

R150 Certificate of patent or registration of utility model

Ref document number: 7808039

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150